Recombinant basic fibroblast growth factor in red blood cell ghosts accelerates incisional wound healing.
The pharmacological manipulation of wound healing with locally applied growth factors is now a practical possibility. The effect of topical applications of recombinant basic fibroblast growth factor (bFGF) on the strength and cellularity of healing incisional rat skin wounds was investigated. Applications of bFGF in a simple vector (either a collagen suspension or saline) were not associated with any positive effects on wound breaking load at 7 days after injury in comparison with vector-treated control wounds; at the highest dose of 50 micrograms per wound, breaking loads were significantly decreased from a mean(s.e.m.) of 287(22) g/cm2 in controls to 201(23) g/cm2 (P < 0.005). Increasing doses of applied peptide were paralleled by increasing wound cellularity. Delay of bFGF release at the site of application was achieved by encapsulation into red blood cell ghosts. Wounds treated with bFGF in such ghosts were 50 per cent stronger than paired control wounds (388(27) versus 256(28) g/cm2, P < 0.002) 7 days after injury. Treated wounds were significantly more cellular at 4 days than paired control wounds. Topical applications of bFGF applied at the time of injury exert a positive effect on incisional wound strength only when a vector that delays release is used.
Slavin
J
J
Department of Surgery, University of Liverpool, UK.
Hunt
J A
JA
Nash
J R
JR
Williams
D F
DF
Kingsnorth
A N
AN
D000287:Administration, Topical; D000818:Animals; D004305:Dose-Response Relationship, Drug; D004910:Erythrocyte Membrane; D016222:Fibroblast Growth Factor 2 / Q000008:administration & dosage / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains; D011994:Recombinant Proteins; D014945:Wound Healing / Q000187:drug effects* / Q000502:physiology
D011994:Recombinant Proteins; D016222:Fibroblast Growth Factor 2